Somatic Symptoms in Autism Spectrum Disorder: Data Integration

NCT ID: NCT05886361

Last Updated: 2023-06-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1423 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-01-01

Study Completion Date

2022-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Autistic patients have higher chances commorbid somatic symptoms. Therefore, it leads to more health-related concerns, such as autoimmune disease, gastrointestinal disease, cardiovascular disease, autonomic disorders. On average, autistic patient's life span is 16 years shorter than non-autistic patients. Furthermore, autistic patients are not able to convey or communicate their somatic symptoms in a clear and comprehensive manner. This leads to unable to receive proper health care in a timely manner.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Autism Spectrum Disorder Somatic Symptom Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ASD

Diagnosed with DSM-5 autism spectrum disorder

No intervention involved

Intervention Type OTHER

No intervention involved

Clinical

Patients with anxiety, depression, somatic symptoms which are non-psychotic and non-organic

No intervention involved

Intervention Type OTHER

No intervention involved

Control

Healthy control without psychiatric disorder or chronic somatic symptoms

No intervention involved

Intervention Type OTHER

No intervention involved

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

No intervention involved

No intervention involved

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ASD group: diagnosed with DSM-5 autism spectrum disorder
* clinical group: anxiety, depression, somatic disorder who are non-psychotic and non-organic
* control group: healthy control without psychiatric disorder or chronic somatic symptoms
* age between 15 and 70

Exclusion Criteria

* psychiatric disorders such as schezophrenia, mood disorder.
* major physical disorder which can be potentially lethal
* who cannot read or comprehend the survey and questionnaire
Minimum Eligible Age

15 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Taiwan University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

202206027RINA

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Cholesterol in ASD: Characterization and Treatment
NCT00965068 COMPLETED PHASE1/PHASE2